La Fondation Bill & Melinda Gates annonce un soutien supplémentaire pour promouvoir la R&D locale. Appels à propositions

BRUXELLES25 octobre 2022 /PRNewswire/ — La Fondation Bill & Melinda Gates a annoncé aujourd’hui une série d’initiatives et un appel à propositions en vue de faire progresser l’innovation locale qui soutient les travaux de scientifiques et de chercheurs dans les économies en développement. L’annonce a été faite lors de la réunion annuelle de Grand Challenges plus tôt aujourd’hui.

La réunion de cette année se concentre sur les enseignements tirés de la pandémie de COVID-19, qui a mis en évidence la nécessité de plateformes de R&D à fort impact, de partenariats et de politiques qui comblent efficacement le fossé existant entre l’innovation et l’accès équitable. La réunion rapproche des chercheurs du monde entier pour partager leurs travaux, en apprendre davantage sur les avancées de pointe dans le domaine des soins de santé et permettre une collaboration avec d’autres chercheurs.

« L’équité en santé ne devrait pas uniquement être un énoncé de la raison pour laquelle nous faisons ce travail. Elle devrait guider la façon dont nous le réalisons », a déclaré Kedest Tesfagiorgis, directeur adjoint des Partenariats mondiaux et des grands défis à la Fondation Bill & Melinda Gates. « Lorsque nous soutenons l’innovation locale, nous maximisons l’impact en mettant en lumière différents types de connaissances et de perspectives. »

Dans le cadre de l’Appel mondial à l’action de Grand Challenges, une initiative sur 10 ans annoncée lors de la réunion de l’année dernière pour aider à s’assurer que les scientifiques et les institutions des pays à revenu faible et intermédiaire (PRFI) jouent un rôle central dans l’élaboration du programme mondial de R&D, deux nouvelles initiatives Grand Challenges ont été annoncée par la fondation :

  • La surveillance génomique des agents pathogènes et l’immunologie en Asie Il s’agit d’une invitation à soumission par les chercheurs en Asie du Sud et du Sud-Est pour concevoir et piloter un programme de surveillance génomique ou de développer des capacités en immunologie et séquençage immunitaire du SRAS-CoV-2 afin d’éclairer la réponse épidémique. Un montant allant jusqu’à 300 000 $ par année pour une période maximale de deux ans seront disponibles pour chaque projet, avec un financement supplémentaire potentiel pour les projets qui mettent l’accent sur la recherche d’anticorps monoclonaux.
  • Le renforcement des capacités de modélisation des données pour l’égalité des sexes  Il s’agit d’un appel à propositions lancé aux chercheurs de pays à revenu faible ou intermédiaire pour des projets visant à éliminer les disparités et les lacunes affectant les femmes et les filles dans le domaine de la santé. Cette initiative est axée sur des approches novatrices de modélisation pour faire progresser l’égalité des sexes. Chaque projet recevra jusqu’à 500 000 $ sur une période d’un à trois ans.

« Les sociétés mesurent ce qu’elles valorisent, et pour une grande partie de l’histoire, la société n’a pas valorisé les femmes. Cela signifie que nous essayons de relever des défis mondiaux en matière de santé et de développement sans disposer de toutes les informations nécessaires », a déclaré Anita Zaidi, présidente du département de l’Égalité des sexes à la Fondation Bill & Melinda Gates. « Il est grand temps de placer les femmes et les filles au centre de la modélisation des données qui guide nos solutions. »

En partenariat avec l’Initiative Chan Zuckerberg (CZI), la fondation accordera également des subventions aux chercheurs qui étudient et détectent les agents pathogènes émergents dans les PRFI. Les chercheurs recevront jusqu’à 200 000 $ chacun, pour une période maximale de deux ans, ainsi que le soutien opérationnel et une formation technique du Biohub Chan Zuckerberg  (CZ Biohub). Cet engagement de financement s’appuie sur un partenariat de 2018 entre la fondation, CZI et le CZ Biohub, qui se concentre sur le renforcement des capacités métagénomiques dans les PRFI par le biais d’une Initiative mondiale Grand Challenges.

La réunion annuelle de Grand Challenges 2022 à Bruxelles est organisée par Global Grand Challenges et la Commission européenne, et est coparrainée par Grands Défis Canada, USAID, Wellcome et la Fondation Bill & Melinda Gates.

L’événement de deux jours réunit des dizaines de leaders du paysage mondial de l’innovation en santé, ainsi que des dirigeants de la Fondation Gates, notamment Bill Gates (coprésident et administrateur), Anita Zaidi et Trevor Mundel (Président, Division de la santé mondiale). Les séances plénières seront publiées peu après la réunion sur le site grandchallenges.org/annual-meeting.

À propos de Grand Challenges

La Fondation Bill & Melinda Gates reconnaît que la résolution des défis les plus urgents en matière de santé et de développement mondiaux nécessite que davantage des esprits les plus brillants du monde y travaillent. La série d’initiatives Grand Challenges cherche à mobiliser des innovateurs du monde entier pour aider à résoudre ces défis. Les initiatives Grand Challenges sont unies par leur volonté de favoriser l’innovation, d’orienter la recherche là où elle aura le plus grand impact et d’aider ceux qui en ont le plus besoin. Pour en savoir plus, visitez le site grandchallenges.org.

À propos de la Fondation Bill & Melinda Gates

Guidée par la conviction que chaque vie a la même valeur, la Fondation Bill & Melinda Gates s’efforce d’aider toutes les personnes à mener une vie saine et productive. Dans les pays en développement, elle vise à améliorer la santé des populations et à leur donner la possibilité de ne plus souffrir de la faim et de l’extrême pauvreté. Aux États-Unis, elle vise à faire en sorte que toutes les personnes, en particulier celles qui ont le moins de ressources, aient accès aux opportunités dont elles ont besoin pour réussir à l’école et dans la vie. Basée à Seattle, Washington, la fondation est dirigée par son PDG Mark Suzman, sous la direction des coprésidents Bill Gates et Melinda French Gates et du Conseil d’administration.

Contact pour les médias : media@gatesfoundation.org

IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on TwitterFacebookLinkedInInstagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

 IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on TwitterFacebookLinkedInInstagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

Rapid Response Mechanism (RRM): Central African Republic, Monthly factsheet #9 (01 – 30 September 2022)

The Rapid Response Mechanism (RRM) is designed to monitor humanitarian action, conduct multisector assessments (MSAs) of needs and to implement several types of emergency responses, including distributions of essential non-food items (NFIs) and high emergency biscuits (HEBs), emergency water, sanitation and hygiene (WASH) interventions, as well as cash transfer programming (CTP). Currently, the RRM is made possible through the support of the United States Agency for International Development (USAID/BHA), the Directorate-General for European Civil Protection and Humanitarian Aid Operations ( DG ECHO), the Swiss Agency for Development and Cooperation (SDC) and the Swedish International Development Cooperation Agency (SIDA). All RRM products are available on the Humanitarian Response portal.

Source: UN Children’s Fund

Labour Minister: Bahrain keen on ensuring protection for all workers

Manama, Labour Minister, Board of Directors Chairman of the Labour Market Regulatory Authority (LMRA), Jameel bin Mohammed Ali Humaidan, today inaugurated the fifth regional “Social Protection for Domestic Workers” conference, organised by the General Federation OF Bahrain Trade Unions (GFBTU) on October 25-26.

Labour Ministry’s Undersecretary, His Highness Shaikh Khalifa bin Salman bin Mohammed Al Khalifa, GFBTU Secretary-General, Abdulqader Abdulkarim Al-Shehabi, representatives of the domestic labour exporting and importing countries, in addition to the representatives of civil society organisations from 11 countries attended the conference.

The conference aims to shed light on national legislation and laws related to expatriate domestic workers in order to enhance cooperation mechanisms between labour organisations in Asia, Africa and the Gulf Cooperation Council (GCC) countries, and to ensure that domestic workers enjoy the same rights enjoyed by their counterparts in other sectors.

 The conference reviewed a research study on the reality of domestic workers in Bahrain, in addition to the legislation in the labour-hosting countries and the extent to which protection for domestic workers is achieved.

Addressing the opening ceremony of the conference, the Labour Minister affirmed Bahrain’s resolve to continue protecting the rights of all workers, based on the system of humanitarian values spearheaded by His Majesty King Hamad bin Isa Al Khalifa, and supported by His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister.

The leadership’s support has resulted in strengthening the foundations and principles of improving working conditions for all workers and preserving their rights without discrimination, which contributed to placing Bahrain among developed countries in providing fair and equitable guarantees for workers, earning it a prestigious status at all international labour gatherings.

He affirmed that the that the Kingdom has issued innumerable laws, procedures and regulations that provide protection for all.

He also highlighted the measures taken by the LMRA to ensure protection for all expatriate workers, including domestic helpers.

GFBTU Secretary-General said that the conference will discuss a number of issues related to domestic labour and their impact on the living situation of citizens.

It will also review a number of studies that contribute to strengthening the preservation of the rights of workers and the employers, he added.

Source: Bahrain News Agency

Security Forum Focuses on Stability Challenges in Africa

Policymakers from around the world met Monday and Tuesday in Senegal to discuss Africa’s most pressing security challenges. This year, attendees of an annual conference focused on redefining the role international partners play in promoting stability in Africa.

More than 1,000 people participated in the eighth edition of the International Forum of Dakar on Peace and Security.

Attendees included the heads of state from Cape Verde, Angola and Guinea-Bissau, as well as high-ranking officials from Japan, Saudi Arabia and France.

The event opened with a speech from Senegalese President and African Union Chairman Macky Sall, who spoke about the need to re-examine modern peace operations.

If U.N. peacekeepers are being attacked on their own bases, they can’t be expected to protect local populations, he said.

“Threats to peace and stability lie in the deep economic crisis that is shaking the world,” Sall said. “Millions of people can no longer bear the cost of living, and others fall into extreme poverty, with no hope of a better future.”

The solution, he said, is to educate and create employment for Africa’s growing youth population.

The conference took place in the wake of France’s withdrawal of military forces from Mali and ongoing criticism of U.N. missions throughout the region.

Militant Islamic violence in Africa has doubled since 2019, with a record 6,300 incidents in 2022 – a 21 percent increase over last year, according to the Africa Center for Strategic Studies, a U.S. Department of Defense research group. The Sahel has been the most impacted, with violent events quadrupling over the same period.

Across the continent close to 15,000 people have died this year from extremist-linked violence, a nearly 50 percent increase from 2019.

Aude Darnal, a fellow with the Stimson Center, a Washington research organization, said of the violence, “Solutions need to be defined by local actors. They also need to be implemented by local actors. International stakeholders should support, but the leadership needs to come from Africa.”

Nadia Adam, a Sahel analyst for the nonprofit Center for Civilians in Conflict, said solutions must be built from the inside. “Most African countries, especially the youth, now want to make decisions for themselves,” she said. “They want to be part of the change. And they have the capacity. More people are educated.”

Government officials attending the conference reiterated that message.

Chidi Blyden is the U.S. assistant secretary of defense for African affairs. In a speech, she quoted a Creole saying from Sierra Leone, which translates to “When and if there’s a problem, look exactly where you’re standing.”

“Some of the problems reside there, but more importantly, the solution probably resides there as well,” she said. “The continent is full of African solutions to global problems.”

The forum also addressed how to decrease Africa’s dependence on international food aid and become more resistant to external shocks, such as the war in Ukraine.

Source: Voice of America

La Plateforme de Yoga française Shiksha® lance son Application et son Réseau Social membre

PARIS , 25 octobre 2022 /PRNewswire/ — Shiksha s’adresse à tous les pratiquants, débutants ou confirmés, qui aspirent à une pratique plus régulière et moins contraignante du yoga. Shiksha leur permet d’améliorer leur pratique personnelle du yoga ou de développer leurs compétences pédagogiques, en qualité de Professeur de yoga.

L’application donne accès à des cours de yoga en ligne, accessibles à la demande ou en direct, pour toutes les personnes recherchant davantage de qualité, de liberté et de commodité dans la découverte ou dans l’approfondissement de sa pratique. Shiksha propose également de nombreuses ressources téléchargeables et MasterClass (e-learning) à destination des professionnels de l’enseignement. Grâce à l’application, les utilisateurs peuvent notamment télécharger les contenus sur leur appareil, les regarder en mode hors connexion et créer leurs propres playlists personnalisées. Les membres de la tribu peuvent échanger entre-eux grâce à un réseau social interne réservé aux membres, y publier leur propres contenus (photos, publications) et notifier instantanément d’autres membres, grâce aux notifications Push par @identifiant utilisateur.

Shiksha se distingue notamment par la qualité éditoriale et technique de ses programmes, présentés sous forme de séries thématiques ou de MasterClass, et réalisés avec des moyens de production professionnels. Shiksha se base sur la technologie de streaming leader du marché (identique à Netflix), afin de garantir une expérience fluide et sans artefacts, quelle que soit la nature de la connexion côté utilisateur. Les cours hebdomadaires diffusés en lives, via un flux HD 1080p, proposent ainsi une expérience immersive et de qualité broadcast.

Shiksha propose une formule découverte totalement gratuite, pour accéder à des séances de méditation hebdomadaires diffusées en direct tous les mercredis matins. Le catalogue de plus de 800 vidéos est quant à lui accessible au moyen d’un abonnement mensuel au tarif de 16,99€/mois. Une formule annuelle à 149,99€ permet de réaliser une économie équivalente à 4 mois d’abonnement, (soit 12,50€/mois). Les abonnements démarrent après une période de gratuité de 14 jours, pendant lesquels l’utilisateur peut librement résilier son abonnement. Les accès aux MasterClass et aux cours en direct sont également possibles par achat unitaire (sans abonnement). Le code SHIKSHA2022, valable pour tout premier abonnement mensuel souscrit via le site Web uniquement, offre 2 mois gratuits jusqu’au 31/12/2022.

Visitez notre site Web : https://shiksha.yoga

Téléchargez l’application mobile :

Contact: namaste@shiksha.yoga

Photo – https://mma.prnewswire.com/media/1926478/Shiksha_Yoga_App.jpg

China in Translation: Exhibition of International Communication Achievements of China Books in the New Era formally kicks off

FRANKFURT, Germany, Oct. 25, 2022 /PRNewswire/ — China in Translation: Exhibition of International Communication Achievements of China Books in the New Era, 2022 formally opened at the Frankfurt Book Fair in Germany on October 19, 2022. Hosted by China National Publications Import and Export (Group) Co., Ltd.(CNPIEC), the five-day event includes a physical book fair and a broadcasting of media videos collection. The physical book fair presents a collection of more than 300 titles originally written in Chinese alongside their translated versions into more than 30 languages, including English, Russian and German, which covers a wide range of topics, such as Chinese economy, literature, history, art and some topics about contemporary China. The media collection displays videos featuring 20 internationally renowned scholars and experts elaborating on topics related to China, including Violeta Bulc, former European Commissioner for mobility and transport of European Commission and former Deputy Prime Minister of Slovenia and Stephan Petermann, advisor of Dutch Creative Industries Fund.

The featured exhibition, a brand project created by CNPIEC and displayed in an exhibit for the first time in 2019, comprehensively presents the publication and promotion of Chinese books in overseas markets from multiple perspectives based on China’s key achievements in the global publishing sector, with the aim of promoting exchanges and collaborations between Chinese and international publishing communities as well as facilitating communications between China and foreign cultures.